News | Ultrasound Imaging | May 28, 2019

Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

Interdisciplinary project seeks to improve outcomes for high-risk prostate cancer patients

Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

May 28, 2019 — Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more precise and personalized. This work will be a critical component of a new interdisciplinary research project funded with $1.4 million from the National Institutes of Health (NIH) that seeks to improve radiation therapy for high-risk prostate cancer patients.

“In order to do precision medicine, you need to see better,” said Pingkun Yan, assistant professor of biomedical engineer at Rensselaer. “If you cannot see, you can’t do anything.”

Yan’s expertise in imaging will support researchers from University of Texas Southwestern, led by Jing Wang, associate professor of radiation oncology, who are currently conducting a clinical trial using an approach known as stereotactic body radiation therapy (SBRT), which delivers high doses of radiation directly to a tumor.

Multiple clinical trials have shown that high doses of radiation to prostate tumors can result in improved cancer outcomes, Yan said, but delivery of that radiation must be localized and precise to protect other healthy tissue nearby.

One of the challenges with SBRT is that the prostate can move and deform during delivery. To make sure the accurate dose is being given in the right location, a reliable and accurate tumor tracking method is needed. But traditional ultrasound technology is not sensitive enough to differentiate between the prostate tumor and healthy tissue.

That’s where Yan comes in. He and his team will develop an imaging method to help researchers distinguish between the healthy tissue and the tumor, so they can more accurately administer the radiation doses.

More specifically, Yan will integrate SBRT with a temporal enhanced ultrasound method (TeUS) that he previously developed through a collaboration with the University of British Columbia, Queens University and NIH. TeUS combines a series of ultrasound images, over time, so that researchers and doctors can visually separate the tumor from the healthy organ.

“The tumor and the healthy tissue move a little differently. By observing that area over time, we extract a difference,” he said.

Deep-learning techniques employed by Yan’s team will make this technique possible.

“We could obtain these images in the past, but didn’t have a good tool to analyze those images. With deep learning, with artificial intelligence, we are now able to decode the information and make it usable,” Yan said.

This research is a prime example of the work being done by Yan and other members of the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer. Yan is also part of a Cancer Research Group within the center.

Yan also recently received a Bench-to-Bedside award grant, also from NIH, to focus on improving cancer detection through ultrasound imaging. He hopes the results of these collaborative, interdisciplinary projects will improve treatment for all patients.

For more information: dial.rpi.edu

Related Content

Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Canon Medical Receives FDA Clearance for AiCE Reconstruction Technology for CT
Technology | Computed Tomography (CT) | June 18, 2019
Canon Medical Systems USA Inc. has received 510(k) clearance on its new deep convolutional neural network (DCNN) image...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
M*Modal and Community Health Network Partner on AI-powered Clinical Documentation
News | PACS Accessories | June 13, 2019
M*Modal announced that the company and Community Health Network (CHNw) are collaborating to transform the patient-...
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Konica Minolta Healthcare Announces Autologous Biologics Workshop in Partnership With EmCyte Corp.
News | Ultrasound Imaging | June 12, 2019
Konica Minolta Healthcare announced a new autologous biologics workshop in partnership with EmCyte Corp. The workshop...